Evotec's Windfall and Restructuring Collide in Pivotal Year

Evotec receives a $100M cash injection from Gilead's Tubulis acquisition, providing crucial funds during its Horizon restructuring program as it aims for profitability.

A surprise cash injection from a major biotech deal is providing crucial breathing room for Evotec SE as it navigates a painful corporate overhaul. The Hamburg-based company stands to receive approximately $100 million upfront, plus up to $58 million in potential milestone payments, from Gilead Sciences' $3.15 billion acquisition of Tubulis. Evotec holds a 3.14% minority stake in the company, stemming from investments made in 2022 and 2024. The transaction's closing is scheduled for the second quarter of 2026.

This liquidity arrives at a critical juncture. Evotec is deep into its "Horizon" restructuring program, which involves closing four of its 14 sites and cutting roughly 800 jobs. The company expects to book associated costs of around €100 million in the latter half of 2026, with annual savings of €75 million anticipated from the end of 2027 onward.

The company's full-year 2025 results, published alongside the Tubulis news, present a mixed financial picture. Group revenue saw a slight decline to €788.4 million. However, adjusted EBITDA improved to €41.1 million, and the net loss was nearly halved to approximately €104 million, down from €196 million the previous year. A stark division in performance between business units drove these figures.

Evotec's biologics division, Just-Evotec Biologics, was a clear standout, with revenue surging 39% to €259.4 million in 2025. In contrast, the traditional drug discovery and development (D&PD) segment struggled, posting a 13.5% revenue decline to €528.9 million.

Management's guidance for the current year frames 2026 as a transitional period. The company forecasts revenue between €700 million and €780 million, with adjusted EBITDA ranging from zero to €40 million. This outlook has contributed to the stock trading approximately 23% below its 200-day moving average.

Analyst sentiment following the reports is divided. While Deutsche Bank Research analyst Fynn Scherzler maintained a "Hold" rating with a €4.50 price target—below the current share price of around €4.74—other firms are more bullish. RBC Capital rates the stock "Outperform" and Berenberg recommends "Buy." The share price had gained about 4.5% on the day of the report, seemingly brushing aside Deutsche Bank's cautious stance.

The focus now shifts sharply to execution in the second half of 2026. Investors will be watching for tangible early effects from the Horizon program and continued stability in the biologics unit. The company has also strengthened its leadership team, appointing Dr. Ashiq H. Khan as Chief Commercial Officer effective April 1. Dieter Weinand, former CEO of Bayer Pharmaceuticals, is slated to be elected as the new Supervisory Board Chairman at the 2026 Annual General Meeting.

Evotec's medium-term ambitions remain ambitious: it is targeting group revenues exceeding one billion euros by 2030 and an adjusted EBITDA margin of 20% by 2028. The coming months, defined by the Tubulis deal closure and the first measurable restructuring impacts, will test the foundation of that long-term plan.